BRIEF—Spain's Grifols awarded another EIB loan

The European Investment Bank (EIB) and Spanish drugmaker Grifols on Friday announced the signing of a new loan agreement for 85 million euros ($99 million) to advance the firm’s R&D efforts to discover new therapeutic uses for plasma proteins in the treatment of rare and chronic diseases.

The agreement is backed by the Investment Plan for Europe.

The loan will support research initiatives that enhance the health and well-being of patients by providing the financial resources necessary to spur innovation in the medical research field in Spain as well as in the rest of the European Union.

The EIB loan represents the third  conceded to Grifols under the umbrella the Investment Plan for Europe, with one amounting to 100 million euros.